A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
A specific anti-neutrophil antibody was recently described in primary sclerosing cholangitis and was detected using an indirect immunoalkaline phosphatase method. The present study examined the relationship of this antibody with respect to time, clinical activity, liver biochemistry, histology and ursodeoxycholic acid treatment. Fourteen patients with primary sclerosing cholangitis were followed up at regular intervals for 2 years. Clinical activity, liver biochemistry, histology and anti-neutrophil antibody titre were determined during the study period. A fluctuating course of the anti-neutrophil antibody was noted in both untreated patients and in those who were on ursodeoxycholic acid. This finding will have clinical implications if anti-neutrophil antibody is used to screen for potential primary sclerosing cholangitis in the future. The results suggest that several determinations of the antibody would need to be carried out over a period of time. No correlation was found between the antibody titre, clinical activity, liver biochemistry or histology. Anti-neutrophil antibody in primary sclerosing cholangitis probably has no pathogenic significance and is an epiphenomenon.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It appears that this antibody is intermittently positive, further limiting its usefulness as a diagnostic test in PSC.45”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [45]
Citations
Cites
Association Between Active Wegener's Granulomatosis and Anticytoplasmic Antibodies
Tervaert, J. W. C. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.11.2461 · Cited by 517
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
Beuers, U., Spengler, U., Kruis, W., Aydemir, Ü., Wiebecke, B., Heldwein, W., Weinzierl, M., Pape, G. R., Sauerbruch, T., & Paumgartner, G. (1992) · Hepatology · doi:10.1002/hep.1840160315 · Cited by 448
Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase [see comments]
Niles, J., McCluskey, R., Ahmad, M., & Arnaout, M. (1989) · Blood · doi:10.1182/blood.v74.6.1888.1888 · Cited by 409
Duerr, R. H., Targan, S. R., Landers, C. J., Larusso, N. F., Lindsay, K. L., Wiesner, R. H., & Shanahan, F. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)70028-v · Cited by 357
Ludwig, J., Barham, S. S., Larusso, N. F., Elveback, L. R., Wiesner, R. H., & McCall, J. T. (1981) · Hepatology · doi:10.1002/hep.1840010612 · Cited by 328
Association of primary sclerosing cholangitis with HLA-B8.
Chapman, R. W., Varghese, Z., Gaul, R., Patel, G., Kokinon, N., & Sherlock, S. (1983) · Gut · doi:10.1136/gut.24.1.38 · Cited by 260
Self-citationPrevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases
Mulder, A. (1993) · Hepatology · doi:10.1016/0270-9139(93)90052-o · Cited by 212
Schrumpf, E., Fausa, O., Førre, Ø., Dobloug, J. H., Ritland, S., & Thorsby, E. (1982) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528209182038 · Cited by 204
Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis
Donaldson, P. T., Farrant, M. J., Wilkinson, M. L., Hayllar, K., Portmann, B. C., & Williams, R. (1991) · Hepatology · doi:10.1002/hep.1840130119 · Cited by 169
Snook, J. A., Chapman, R. W., Fleming, K. A., & Jewell, D. P. (1989) · PubMed Central · Cited by 110
Self-citation
Research works printed but not linked: 4
- Mehal, 1991, Inability to attribute susceptibility to primary sclerosing cholangitis to specific amino acid positions of the HLA-DRw52a allele (letter), N Eng J Med, 325, 1252
- Sharma, 1991, Perinuclear anti-neutrophil cytoplasmic antibodies in primary sclerosing cholangitis, Hepatology, 14, 64A
- Stiehl, 1989, Treatment of primary sclerosing cholangitis with ursodeoxycholic acid: first results of a controlled study (Abstract), Hepatology, 10, 602
- Colombel, 1992, Influence of disease activity on presence of perinuclear antineutrophil cytoplasmic autoantibodies in sera from repeatedly tested patients with ulcerative colitis (Abstract), Gastroenterology, 102, A608
Cited by
Primary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Autoantibodies in primary sclerosing cholangitis
Hov, J. R., Boberg, K. M., & Karlsen, T. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3781 · Cited by 187
Metadata
- Authors
- Lo, S. K., Fleming, K. A., & Chapman, R. W.
- Affiliations
- John Radcliffe Hospital (GB)
- Corresponding author
- Chapman, Roger W.
- ORCID
- Chapman, Roger W.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 1994-01
- Volume
- 21
- Issue
- 6
- Pages
- 974-978
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2091476871
- Cited by
- 50
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2015: 4 · 2012: 1
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary sclerosing cholangitis, antineutrophil antibodies, ursodeoxycholic acid, disease activity, liver biochemistry, liver histopathology, screening marker
- MeSH terms
- Adult, Aged, Autoantibodies, Female, Follow-Up Studies, Humans, Immunohistochemistry, Liver, Male, Middle Aged, Ursodeoxycholic Acid, Cholangitis, Sclerosing, Biomarkers, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment. https://app.cochat.ai/papers/10.1016/s0168-8278(05)80604-x
- The paper
- Lo, S. K., Fleming, K. A., & Chapman, R. W. (1994). A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(05)80604-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.